* was admitted to a hospital for covid-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization * has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, mabs against sars-cov-2 (eg, bamlanivimab), or intravenous immunoglobulin (ivig) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit * prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2 (eg, bamlanivimab), ivig (any indication), systemic corticosteroids (any indication), or covid-19 treatments (authorized, approved, or investigational) * prior use (prior to randomization), current use (at randomization) or planned use (within 90 days of study drug administration or per current cdc recommendations, as applicable) of any authorized or approved vaccine for covid-19 * has participated, is participating or plans to participate in a clinical research study evaluation any authorized, approved or investigational vaccine for covid-19 note: other protocol defined inclusion/exclusion criteria apply

* was admitted to a hospital for covid-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization * has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, mabs against sars-cov-2 (eg, bamlanivimab), or intravenous immunoglobulin (ivig) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit * prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2 (eg, bamlanivimab), ivig (any indication), systemic corticosteroids (any indication), or covid-19 treatments (authorized, approved, or investigational) * prior use (prior to randomization), current use (at randomization) or planned use (within 90 days of study drug administration or per current cdc recommendations, as applicable) of any authorized or approved vaccine for covid-19 * has participated, is participating or plans to participate in a clinical research study evaluation any authorized, approved or investigational vaccine for covid-19 note: other protocol defined inclusion/exclusion criteria apply

- was admitted to a hospital for covid-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, mabs against sars-cov-2 (eg, bamlanivimab), or intravenous immunoglobulin (ivig) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit - prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2 (eg, bamlanivimab), ivig (any indication), systemic corticosteroids (any indication), or covid-19 treatments (authorized, approved, or investigational) - prior use (prior to randomization), current use (at randomization) or planned use (within 90 days of study drug administration or per current cdc recommendations, as applicable) of any authorized or approved vaccine for covid-19 - has participated, is participating or plans to participate in a clinical research study evaluation any authorized, approved or investigational vaccine for covid-19 note: other protocol defined inclusion/exclusion criteria apply

- was admitted to a hospital for covid-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, mabs against sars-cov-2 (eg, bamlanivimab), or intravenous immunoglobulin (ivig) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit - prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2 (eg, bamlanivimab), ivig (any indication), systemic corticosteroids (any indication), or covid-19 treatments (authorized, approved, or investigational) - prior use (prior to randomization), current use (at randomization) or planned use (within 90 days of study drug administration or per current cdc recommendations, as applicable) of any authorized or approved vaccine for covid-19 - has participated, is participating or plans to participate in a clinical research study evaluation any authorized, approved or investigational vaccine for covid-19 note: other protocol defined inclusion/exclusion criteria apply

- was admitted to a hospital for covid-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, mabs against sars-cov-2 (eg, bamlanivimab), or intravenous immunoglobulin (ivig) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit - prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2 (eg, bamlanivimab), ivig (any indication), systemic corticosteroids (any indication), or covid-19 treatments (authorized, approved, or investigational) - prior use (prior to randomization), current use (at randomization) or planned use (within 90 days of study drug administration or per current cdc recommendations, as applicable) of any authorized or approved vaccine for sars-cov-2 - has participated, is participating or plans to participate in a clinical research study evaluation any authorized, approved or investigational vaccine for sars-cov-2 note: other protocol defined inclusion/exclusion criteria apply

- was admitted to a hospital for covid-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, mabs against sars-cov-2 (eg, bamlanivimab), or intravenous immunoglobulin (ivig) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit - prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2 (eg, bamlanivimab), ivig (any indication), systemic corticosteroids (any indication), or covid-19 treatments (authorized, approved, or investigational) - prior use (prior to randomization), current use (at randomization) or planned use (within 90 days of study drug administration or per current cdc recommendations, as applicable) of any authorized or approved vaccine for sars-cov-2 - has participated, is participating or plans to participate in a clinical research study evaluation any authorized, approved or investigational vaccine for sars-cov-2 note: other protocol defined inclusion/exclusion criteria apply

- was admitted to a hospital for covid-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, mabs against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit - prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2, ivig (any indication), systemic corticosteroids (any indication), or covid-19 treatments (authorized, approved, or investigational) note: other protocol defined inclusion/exclusion criteria apply

- was admitted to a hospital for covid-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, mabs against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit - prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2, ivig (any indication), systemic corticosteroids (any indication), or covid-19 treatments (authorized, approved, or investigational) note: other protocol defined inclusion/exclusion criteria apply

- has been admitted to a hospital prior to randomization, or is hospitalized (inpatient) at randomization, due to covid-19 - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit - prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2, ivig (any indication), systemic corticosteroids (any indication), or covid-19 eua approved treatments, where prior use is defined as the past 30 days or less than 5 half-lives of the investigational product (which is longer) from screening note: other protocol defined inclusion/exclusion criteria apply

- has been admitted to a hospital prior to randomization, or is hospitalized (inpatient) at randomization, due to covid-19 - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit - prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2, ivig (any indication), systemic corticosteroids (any indication), or covid-19 eua approved treatments, where prior use is defined as the past 30 days or less than 5 half-lives of the investigational product (which is longer) from screening note: other protocol defined inclusion/exclusion criteria apply